TORONTO, ONTARIO–(Marketwired – Feb. 28, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:FOIFF) a portfolio based biotechnology company, announced today it has raised $400,000 with the closing of the non-brokered private placement the Company announced in a press release February 21, 2017 (The “Offering”).
Press Releases
Arch Biopartners Announces TSXV Stock Ticker Symbol Change to “ARCH”
TORONTO, ONTARIO–(Marketwired – Feb. 23, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company, announced today that the Company’s common shares will begin trading under the new stock ticker symbol “ARCH” on the TSX Venture Exchange (TSXV), effective at the open of trading on February 24, 2017.
Arch Biopartners Announces Non-Brokered Private Placement Financing
TORONTO, ONTARIO–(Marketwired – Feb. 21, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 1,000,000 common shares priced at $0.40 per common share (the “Common Shares”) for gross proceeds of up to $400,000 (the “Offering”).
Arch Biopartners Appoints Patrick Vink to Board of Directors
TORONTO, CANADA–(Marketwired – Dec. 12, 2016) – Arch Biopartners, Inc., (TSX VENTURE:ACH) (OTCBB:FOIFF) (Arch or the Company) is pleased to announce that Dr. Patrick Vink has joined its Board of Directors effective December 12th, 2016.
Arch Biopartners Collaborates With Team at Cincinnati Veterans Affairs Medical Center to Prepare Phase I and II Human Trial Protocol and Application for AB569
TORONTO, ONTARIO–(Marketwired – Oct. 27, 2016) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced it has agreed to sponsor Dr. Ralph Panos and his clinical trial team at the Cincinnati Veterans Affairs Medical Center (CVAMC) to prepare a phase I and phase II human trial protocol and an application to conduct investigator initiated trials evaluating the safety and efficacy of AB569.
Arch Biopartners Announces Issuance of U.S. Patent for Metablok
TORONTO, CANADA–(Marketwired – Oct. 11, 2016) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH) (OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 9,464,114 titled, “Peptides that Block Leukocyte Recruitment and Methods of Use”.
Arch Biopartners Engages Catalent to Begin Manufacturing Process for AB569
TORONTO, ONTARIO–(Marketwired – Aug. 10, 2016) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced it has engaged Catalent Inhalation, a division of Catalent Pharma Solutions (Catalent), to begin the manufacturing process for its drug AB569 in preparation for the first human trials involving patients with antibiotic resistant lung infections.
Arch Biopartners Forms Clinical and Medical Advisory Board for AB569
TORONTO, ONTARIO–(Marketwired – July 18, 2016) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced the formation of a clinical and medical advisory board for AB569, the Company’s bactericidal drug for treating antibiotic resistant infections in lungs and the urinary tract.
Arch “Borg” Peptide Coating Displays Anti Corrosion Performance on Stainless Steel
TORONTO, ONTARIO–(Marketwired – July 5, 2016) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced that scientists at a corrosion research laboratory have confirmed that Arch’s ‘Borg’ peptides display significant anti-corrosion performance on stainless steel.
Arch Biopartners’ AB569 Receives Final Approval from European Commission for Orphan Designation for Cystic Fibrosis
TORONTO, ONTARIO–(Marketwired – June 1, 2016) – Arch Biopartners Inc. (Arch, or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced the European Commission has designated AB569 as an orphan medicinal product in the European Union for the treatment of patients with cystic fibrosis (CF).